The research program was developed in 1995 to explore additional treatment options for patients of the practice. In March 2015, we joined the National Community Oncology Research Program (NCORP), essentially establishing a small satellite of the National Cancer Institute (NCI) in Pismo Beach. This increases access to new NCI-sponsored clinical trials for local patients. Because of efficiencies in the NCORP, overhead for the research program will decrease, permitting us to use more of our resources for research and patient services. We also remain active in the Mayo Clinic's Academic and Community Cancer Research United (ACCRU) network.

In addition to the trials listed we have access to about 75 clinical trials reviewed by the NCI CIRB.  If you are interested in a clinical trial that is not listed ask Sarah Estrada (Sarah@PCROncology.com) if we have access to it.


Open Clinical Trials as of January 2019



  • INCB 50465-201: A phase II study of the safety, tolerability, and efficacy of INCB050465 in combination with Ruxolitinib in subjects with Myelofibrosis.

  • E4412: A phase I study with an expansion cohort/randomized phase II study of the combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in patients with relapsed/refactory Hodgkin Lymphoma.


  • A011502: A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer: The ABC trial.

  • S1418: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer.


  • EAY 131: Molecular Analysis for Therapy Choice (MATCH)


  • A021502 - Adjuvant chemotherapy for MSI-high or mismatch-repair deficient stage III colon cancer with standard chemotherapy with or without atezolimumab (immunotherapy).


  • ECOG 4512-A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A081105-Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC).


  • A021502: Randomized trial of standard chemotherapy alone or combined with Atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair.

  • PP06490: A phase III double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6(5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patients with first-line metastatic colorectal cancer.


  • EA8153: Cabazitaxel with Abiraterone verses Abiraterone alone randomized trial for extensive disease following Docetaxel: the CHAARTED2 Trial.


  • EA6141-Randomized Phase II/III study of nivolumab plus ipilimumab with or without sargramostim in patients with unresectable stage III or stage IV melanoma


For more information please contact:
Sarah Estrada at Sarah@pcroncology.com or call (805) 474-9143